Canopy Growth Corp (CGC) shares exploded Friday morning after reports emerged that President Donald Trump intends to ease federal marijuana regulations. It's the kind of news that can make cannabis investors feel like they've been waiting forever for the other shoe to drop, and finally it might be happening.

What's Driving the Rally

The surge comes courtesy of a Washington Post report indicating Trump is preparing to instruct federal agencies to reclassify marijuana as a Schedule III drug. That might sound like bureaucratic jargon, but the financial implications are massive.

Right now, cannabis sits in the same regulatory category as heroin, which creates absolutely brutal tax consequences for companies trying to run legitimate businesses. The specific financial driver here isn't just vibes about legalization. It's about corporate taxation and capital flow.

Moving marijuana to Schedule III, a category that includes drugs with accepted medical uses like steroids or Tylenol with codeine, would fundamentally change how Canopy Growth gets taxed. Investors are betting this shift will significantly improve the company's bottom line by eliminating the fiscal handicaps that have plagued cannabis companies for years.

Beyond Tax Relief

The regulatory change could do more than just ease the tax burden. It might attract fresh investment into the sector, giving companies like Canopy easier access to capital. According to Axios, this change is expected to happen early next year, which gives the market an actual timeline instead of vague promises.

While the entire sector is rallying with peers like Tilray and Aurora also surging, CGC investors are specifically pricing in the benefits of a normalized operating environment. This is about treating cannabis as a legitimate pharmaceutical product rather than a dangerous illicit substance, which changes everything from banking relationships to institutional investment appetite.

Price Movement and Technical Picture

Canopy Growth shares were up 37.2% at $1.55 at the time of publication Friday, according to market data.

The stock is trading approximately 13.2% above its 50-day moving average of $1.23, suggesting the recent surge has positioned Canopy favorably in the short term. It's also sitting about 9.7% above its 200-day moving average of $1.27, indicating strength relative to its longer-term trend as well.

For a sector that's been beaten down and waiting for regulatory relief, this news represents the kind of catalyst that could finally change the narrative. Whether it translates into sustained gains depends on how quickly the reclassification actually happens and what the practical impacts look like for companies still navigating a complex legal landscape.